{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:12:40Z","timestamp":1790993560503,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01212-1","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:21:51Z","timestamp":1719429711000},"page":"1945-1957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Disease Course, Treatment Patterns and Goals Among Patients with Non-segmental Vitiligo Across Europe and the United States"],"prefix":"10.1007","volume":"14","author":[{"given":"David","family":"Rosmarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi S.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"1212_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236:571\u201392.","journal-title":"Dermatology"},{"key":"1212_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"KEV Ezzedine","year":"2015","unstructured":"Ezzedine KEV, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74\u201384.","journal-title":"Lancet"},{"key":"1212_CR3","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya A, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36:1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1212_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159:1124\u20138.","journal-title":"JAMA Dermatol"},{"key":"1212_CR5","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/jdv.19447","volume":"37","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Seneschal J, Da Silva A, et al. Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort. J Eur Acad Dermatol Venereol. 2023;37:2249\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1212_CR6","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s13555-023-01001-2","volume":"13","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Soliman AM, Li C, Camp HS, Pandya AG. Comorbidity burden among patients with vitiligo in the United States: a large-scale retrospective claims database analysis. Dermatol Ther (Heidelb). 2023;13:2265\u201377.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1212_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jdv.16927","volume":"35","author":"V Narayan","year":"2021","unstructured":"Narayan V, Uitentuis S, Luiten R, Bekkenk M, Wolkerstorfer A. Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35:744\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1212_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22:757\u201374.","journal-title":"Am J Clin Dermatol"},{"key":"1212_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/bjd\/ljad109","volume":"189","author":"S Merhi","year":"2023","unstructured":"Merhi S, Salameh P, Abboud M, et al. Facial involvement is reflective of patients\u2019 global perception of vitiligo extent. Br J Dermatol. 2023;189:188\u201394.","journal-title":"Br J Dermatol"},{"key":"1212_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jid.2023.08.025","volume":"144","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Soliman AM, Li C, Camp HS, Pandya AG. Economic burden among patients with vitiligo in the United States: a retrospective database claims study. J Invest Dermatol. 2023;144:540\u20136.","journal-title":"J Invest Dermatol"},{"key":"1212_CR11","unstructured":"Incyte. Incyte announces FDA approval of Opzelura (Ruxolitinib) cream for the treatment of vitiligo. Available from: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream-0 (2022). Accessed 1 Feb 2024."},{"key":"1212_CR12","unstructured":"Incyte. European commission approval of opzelura (ruxolitinib) cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents. Available from: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-announces-european-commission-approval-opzelurar (2023). Accessed 1 Feb 2024."},{"key":"1212_CR13","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s13555-023-00983-3","volume":"13","author":"D Rosmarin","year":"2023","unstructured":"Rosmarin D, Soliman A, Li C. Real-world treatment patterns in patients with vitiligo in the United States. Dermatol Ther (Heidelb). 2023;13:2079\u201391.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1212_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3892\/etm.2021.10229","volume":"22","author":"DE Kubelis-L\u00f3pez","year":"2021","unstructured":"Kubelis-L\u00f3pez DE, Zapata-Salazar NA, Said-Fern\u00e1ndez SL, et al. Updates and new medical treatments for vitiligo (review). Exp Ther Med. 2021;22:797.","journal-title":"Exp Ther Med"},{"key":"1212_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/bjd\/ljad245","volume":"189","author":"IH Hamzavi","year":"2023","unstructured":"Hamzavi IH, Bibeau K, Grimes P, et al. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. Br J Dermatol. 2023;189:569\u201377.","journal-title":"Br J Dermatol"},{"key":"1212_CR16","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2013a means to understand. Curr Med Res Opin. 2008;24:3063\u201372.","journal-title":"Curr Med Res Opin"},{"key":"1212_CR17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39:1707\u201315.","journal-title":"Curr Med Res Opin"},{"key":"1212_CR18","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13555-022-00752-8","volume":"12","author":"H Kitchen","year":"2022","unstructured":"Kitchen H, Wyrwich KW, Carmichael C, et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the vitiligo area scoring index (VASI). Dermatol Ther (Heidelb). 2022;12:1623\u201337.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01212-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T17:20:24Z","timestamp":1721496024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01212-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01212-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Rosmarin has consulted, spoken for, or conducted trials for AbbVie, Abcuro, AltruBio, Amgen, Arena, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio, Zura Bio. Ahmed M. Soliman and Heidi S. Camp are full-time employees of AbbVie and may hold AbbVie stock and\/or stock options or patents. Khaled Ezzedine declares acting as a consultant for Incyte, La Roche Posay, Pfizer, Pierre Fabre, Almirall, MSD, BMS, and AbbVie. Simran Marwaha, James Piercy, and Peter Anderson are employees of Adelphi Real World.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This analysis was conducted on existing de-identified data; therefore, the study team did not have access to any personal information on the patients or physicians and as such this study did not require ethics committee approval. As part of the DSP, patients were asked to complete a declaration page where they agreed to partake in the completion of the patient self-completion form in accordance with HIPAA and equivalent European Union guidelines. The DSP was submitted to the Pearl institutional review board. National data collection regulations were adhered to (European Society for Opinion and Market Research; US Department of Health and Human Services National Institutes of Health HIPAA; The Market Research Society; British Standards Institute).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}